Annual direct medical costs of bronchiectasis treatment

Chronic Respiratory Disease

Volumn 13, Issue 4, 2016, Pages 361-371

  De La Rosa, David ^a   Martínez Garcia, Miguel Angel ^b   Olveira, Casilda ^c   Girón, Rosa ^d   Máiz, Luis ^e   Prados, Concepción ^f  

^a HOSPITAL PLATÓ   (Spain)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

^c HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^d HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^e HOSPITAL RAMÓN Y CAJAL   (Spain)

^f HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

antibacterial agents; bronchiectasis; disease exacerbation; inhalation drug administration; Pharmacoeconomics; Pseudomonas aeruginosa

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CIPROFLOXACIN; CORTICOSTEROID; LEVOFLOXACIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BACTERIAL COLONIZATION; BREATHING EXERCISE; BRONCHIECTASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH CARE COST; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; OXYGEN THERAPY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY;

EID: 84994030731     PISSN: 14799723     EISSN: 14799731     Source Type: Journal    
DOI: 10.1177/1479972316643698     Document Type: Article

References (40)

1. Martínez-García MA, Soler-Cataluña JJ, Perpiñá-Tordera M, et al. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest 2007; 132 (5): 1565-1572.
2. Haworth CS, Foweraker JE, Wilkinson P, et al. Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. Am J Respir Crit Care Med 2014; 189 (8): 975-982.
3. Olveira C, Olveira G, Espildora F, et al. Validation of a Quality of Life Questionnaire for Bronchiectasis: psychometric analyses of the Spanish QOL-B-V3.0. Qual Life Res 2014; 23 (4): 1279-1292.
4. Martínez-García MA, Perpiñá-Tordera M, Soler-Cataluña JJ, et al. Dissociation of lung function, dyspnea ratings and pulmonary extension in bronchiectasis. Respir Med 2007; 101 (11): 2248-2253.
5. King PT, Holdsworth SR, Freezer NJ, et al. Microbiologic follow-up study in adult bronchiectasis. Respir Med 2007; 101 (8): 1633-1638.
6. Roberts HR, Wells AU, Milne DG, et al. Airflow obstruction in bronchiectasis: correlation between computed tomography features and pulmonary function tests. Thorax 2000; 55 (3): 198-204.
7. Martínez-García MA, de Gracia J, Vendrell Relat M, et al. Multidimensional approach to non-cystic fibrosis bronchiectasis. The FACED score. Eur Respir J 2014; 43 (5): 1357-1367.
8. Weycker D, Edelsberg J, Oster G, et al. Prevalence and economic burden of bronchiectasis. Clin Pulm Med 2005; 12 (4): 205-209.
9. Joish VN, Spilsbury-Cantalupo M, Operschall E, et al. Economic burden of non-cystic fibrosis bronchiectasis in the first year after diagnosis from a US health plan perspective. Appl Health Econ Health Policy 2013; 11 (3): 299-304.
10. Seitz AE, Olivier KN, Steiner CA, et al. Trends and burden of bronchiectasis-associated hospitalizations in the United States, 1993-2006. Chest 2010; 138 (4): 944-949.
11. Miravitlles M, Murio C, Guerrero T, et al. Costs of chronic bronchitis and COPD: a 1-year follow-up study. Chest 2003; 123 (3): 784-791.
12. Izquierdo JL, de-Miguel J,. Economic impact of pulmonary drugs on direct costs of stable chronic obstructive pulmonary disease. COPD 2004; 1 (2): 215-223.
13. Menn P, Heinrich J, Huber RM, et al.; KORA Study Group. Direct medical costs of COPD-An excess cost approach based on two population studies. Respir Med 2012; 106 (4): 540-548.
14. Pasquale MK, Sun SX, Song F, et al. Impact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly medicare population. Int J Chron Obstruct Pulmon Dis 2012; 7: 757-764.
15. Hill AT, Welham S, Reid K, et al.; British Thoracic Society. British Thoracic Society national bronchiectasis audit 2010 and 2011. Thorax 2012; 67 (10): 928-930.
16. Sidhu MK, Mandal P, Hill AT,. Bronchiectasis: an update on current pharmacotherapy and future perspectives. Expert Opin Pharmacother 2014; 15 (4): 505-525.
17. Seitz AE, Olivier KN, Adjemian J, et al. Trends in bronchiectasis among medicare beneficiaries in the United States, 2000 to 2007. Chest 2012; 142 (2): 432-439.
18. Quint JK, Millett E, Hurst JR, et al. Time trends in incidence and prevalence of bronchiectasis in the UK [abstract]. Thorax 2012; 67 (Suppl 2): A138.
19. Ringshausen FC, de Roux A, Pletz MW, et al. Bronchiectasis-associated hospitalizations in Germany, 2005-2011: a population-based study of disease burden and trends. PLoS One 2013; 8 (8): e71109.
20. Drummond M, Manca A, Sculpher M,. Increasing the generalizability of economic evaluations: recommendations for the design, analysis, and reporting of studies. Int J Technol Assess Health Care 2005; 21 (2): 165-171.
21. Petrou S, Gray A,. Economic evaluation alongside randomised controlled trials: design, conduct, analysis, and reporting. BMJ 2011; 342: d1548.
22. Wilson R, Welte T, Polverino E, et al. Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study. Eur Respir J 2013; 41 (5): 1107-1115.
23. Serisier DJ, Bilton D, De Soyza A, et al.; ORBIT-2 investigators. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. Thorax 2013; 68 (9): 812-817.
24. Bilton D, Tino G, Barker AF, et al.; B-305 Study Investigators. Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial. Thorax 2014; 69 (12): 1073-1079.
25. Naidich DP, McCauley DI, Khouri NF, et al. Computed tomography of bronchiectasis. J Comput Assist Tomogr 1982; 6 (3): 437-444.
26. Vendrell M, de Gracia J, Olveira C, et al. Diagnosis and treatment of bronchiectasis. Spanish Society of Pneumology and Thoracic Surgery. Arch Bronconeumol 2008; 44 (11): 629-640.
27. Ministry of Health, Social Services and Equality. Statistical Site of the NHS. Available at: http://pestadistico.inteligenciadegestion.msssi.es/ (. accessed 4 January 2015).
28. Order of October 14th, 2005, by which public prices of health services provided by centers under the Andalusian Public Health System are set. Official Bulletin of the Government of Andalusia. 27 October 2005, no. 210., p. 46.
29. Order SLT/42/2012 of February 24rd, which regulates the assumptions and concepts billable and approves the public prices corresponding to the services provided by the Catalan Institute of Health. Official Journal of the Government of Catalonia. 2 March 2012, no. 6079, p. 10706.
30. Law 5/2013 of December 23 rd, of Fiscal Measures, of Administrative and Financial Management, and of Organization of the Generalitat. Official Journal of the Valencian Community. 27 December 2013, no. 7181, p. 36212.
31. Order 731/2013, of September 6th, by which the public prices for the provision of health services and healthcare activities of the Network of Centers of the Community of Madrid are set. Official Bulletin of the Community of Madrid. 10 September 2013, no. 215, p. 8.
32. Miravitlles M, Murio C, Guerrero T, et al. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest 2002; 121 (5): 1449-1455.
33. Masa JF, Sobradillo V, Villasante C, et al. Costs of chronic obstructive pulmonary disease in Spain. Estimation from a population-based study. Arch Bronconeumol 2004; 40 (2): 72-79.
34. Løkke A, Hilber O, Tønnesen P, et al. Direct and indirect economic and health consequences of COPD in Denmark: a national register-based study: 1998-2010. BMJ Open 2014; 4 (1): e004069.
35. Charlson ME, Charlson RE, Paterson JC, et al. The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients. J Clin Epidemiol 2008; 61 (12): 1234-1240.
36. Martínez-García MÁ Soler-Cataluña JJ, Donat Sanz Y, et al. Factors associated with bronchiectasis in patients with COPD. Chest 2011; 140 (5): 1130-1137.
37. Pasteur MC, Bilton D, Hill AT, British Thoracic Society Bronchiectasis non-CF Guideline Group. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010; 65 (Suppl 1): i1-58.
38. Lavery KA, O'Neill B, Parker M, et al. Expert patient self-management program versus usual care in bronchiectasis: a randomized controlled trial. Arch Phys Med Rehabil 2011; 92 (8): 1194-1201.
39. Mandal P, Sidhu MK, Donaldson LS, et al. Eight-weekly intravenous antibiotics is beneficial in severe bronchiectasis. QJM 2013; 106 (1): 27-33.
40. Garcha DS, Thurston SJ, Patel AR, et al. Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD. Thorax 2012; 67 (12): 1075-1080.